Kiran Jagarlamudi

Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial

Laurent Peyrin‐Biroulet, Ailsa Hart, Peter Bossuyt et al. · ˜The œLancet. Gastroenterology & hepatology · 2021 · 89 citations · Full text

Inflammation, Anti-inflammatory, Immunology +7

Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker

Kiran Jagarlamudi, Lars O. Hansson, Staffan Eriksson · BMC Cancer · 2015 · 47 citations · Full text

Quaternary structures of recombinant, cellular, and serum forms of Thymidine Kinase 1 from dogs and humans

Sharif Hanan, Kiran Jagarlamudi, Liya Wang et al. · BMC Biochemistry · 2012 · 24 citations · Full text

A Dual Biomarker TK1 Protein and CA125 or HE4-Based Algorithm as a Better Diagnostic Tool than ROMA Index in Early Detection of Ovarian Cancer

Diana Cviič, Kiran Jagarlamudi, Leon Meglič et al. · Cancers · 2023 · 16 citations · Full text

A New Sandwich ELISA for Quantification of Thymidine Kinase 1 Protein Levels in Sera from Dogs with Different Malignancies Can Aid in Disease Management

Kiran Jagarlamudi, Laura Moreau, Sara Westberg et al. · PLoS ONE · 2015 · 14 citations · Full text

Disease Management, Solid Tumors, Immunology +18